Stockreport

Oculis Reports Q4 and Full Year 2023 Financial Results and Update on Company Progress

Oculis Holding AG  (OCS) 
PDF A successful year including NASDAQ listing and positive results from two Phase 3 programs in OCS-01: Phase 3 Stage 1 DIAMOND trial for Diabetic Macular Edema (DME), and [Read more]